Association for Natural Medicine in Europe
ANME
The Association for Natural Medicine in Europe e.
ID: 782765412493-49
Lobbying Activity
Response to Pharmaceutical Strategy - Timely patient access to affordable medicines
6 Jul 2020
In the name of European patients and professional providers in the field of a sustainable, holistic, individual person-centered and forward-looking strategy for access to affordable medicines, we have identified the following key-demanding:
1. In the last twenty-five years Natural Medicine/CAM has suffered the loss of thousands of traditional and medicinal products. We want them back! E.g. there is no longer a BSE-epidemic which cuts organic medicinal products.
2. The doses of a Natural Medicines/CAM medical product depend of the individual need of patients. We need a harmonisation of national and European regulation.
3. A new EU-pharmaceutical strategy should include a separate chapter for CAM and its medicinal and other products. It would be crucial to develop a design for research and studies for Natural Medicine/CAM`s own, respecting the specific circumstances and needs. On top the inclusion of additional effects by the composition of medicinal products.
4. We welcome the COMMISSION STAFF WORKING DOCUMENT EXECUTIVE SUMMARY OF THE EVALUATION of the Regulation (EC) No 1924/2006 on nutrition and health claims made on foods with regard to nutrient profiles and health claims made on plants and their preparations and of the general regulatory framework for their use in foods, hoping for support and a fruitful together with CAM-stakeholders.
With kind regards
Nora Laubstein
Read full responseResponse to Pharmaceutical Strategy - Timely patient access to affordable medicines
25 Jun 2020
Dear Commissioner Stella Kyriakidis,
yes there is a need to build a holistic, individual patient-centered, forward-looking EU Pharmaceutical Strategy which covers the whole life-cycle of pharmaceutical products from scientific discovery to authorization and patient access including sustainable medicines and remedies too. First I have to mention some challenges related to the current legislation:
Directive 2004/24/EC (THMPD-herbal preparations) as a body of rules enabling a simplified registration of natural products with long term tradition. Inside the attached file you will find my concrete suggestions for a better EU-pharmaceutical strategy.
Second: The new strategy should ensure the sound functioning of the internal market and the sustainability of public finances AND the environment. It will create synergies with relevant EU policies, such as in the areas of agriculture, air pollution, clear water and the reducing of plastic-waste. The coherence will be kept with EU clinical trials respecting the biological and physical regulation of human and animal beings.
The idea of a “New Green Deal” and the implementation via SDG`s into the “Health in all policies”-project should be based crucial on the interdisciplinary aspects of natural medicine, products and prevention!
Sincerely, Nora Laubstein, Association for Natural Medicine in Europe-ANME e.V.
Read full response